Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy ...
Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.
Four industry lobbyists said that based on feedback from pharmaceutical companies, mid-sized and smaller drugmakers have not ...
By Michael Erman and Deena Beasley NEW YORK/SAN DIEGO, June 30 (Reuters) - President Donald Trump has promised to make U.S.
A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...
The company also experienced a recent setback with sigvotatug vedotin failing to meet the primary endpoint in a phase 3 study targeting previously treated non-small cell lung cancer (NSCLC). There's ...
Lupin rose 2.21% to Rs 2,393.80 after it has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in ...
The USFDA has tentatively approved the 40 mg and 80 mg strengths as bioequivalent to Xtandi Tablets of Astellas.
Lupin's shares rose as the USFDA granted tentative approval for its Enzalutamide tablets, offering new dosing options alongside bioequivalent alternatives to Xtandi.
The sizable yield comes with a concerning footnote. Just look at the rest of the story.
The U.S. FDA has tentatively approved Lupin's Enzalutamide Tablets, 40 mg and 80 mg as bioequivalent to reference listed drug (RLD) Xtandi® Tablets of Astellas for the indication in the approved ...
Lupin secures tentative USFDA approval for generic enzalutamide tablets for castration‑resistant prostate cancer, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results